Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | RXRA | P19793 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | CCKAR | P32238 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1786786 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL5056806 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL29380299 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL31002987 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147655 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL556763 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL6251405 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41503 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41502 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147661 | 0.99 | CYP2C9 (0.98) | CYP2C9KDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3877 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119951592-A | Preparation method of catalytic material for photocatalytic degradation of carbamazepine in sewage | 北方工业大学 | 2025-05-09 | — | — | CN | claimed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| CN-119185228-A | Fluvastatin sodium sustained release tablet and preparation method thereof | 杭州泓友医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-221999480-U | Purification device is used in fluvastatin sodium tablet production | 广州誉东健康制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| EP-4445959-A2 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | Catalent Ontario Limited (CA) | 2024-10-16 | — | — | EP | claimed |
| US-20240317684-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF FLUVASTATIN SODIUM SALT | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2024-09-26 | — | — | US | claimed |
| EP-4434967-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF FLUVASTATIN SODIUM SALT | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2024-09-25 | — | — | EP | claimed |
| CN-118684614-A | Process for preparing crystalline form of fluvastatin sodium salt | F.I.S.-菲博利佳意大利合成面料股份公司 | 2024-09-24 | — | — | CN | claimed |
| EP-3581173-B1 | PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION | CATALENT ONTARIO LTD (CA) | 2024-08-28 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2001056547-A2 | PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS | YOO SEO HONG (US) | 2001-08-09 | — | — | WO | claimed |
| US-6124340-A | FLUVASTATIN SODIUM FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | claimed |
| EP-0547000-B1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | NOVARTIS AG (CH) | 2000-02-02 | — | — | EP | claimed |
| EP-0907639-A1 | POLYMORPHIC COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-04-14 | — | — | EP | claimed |
| CN-1041794-C | Stabilized pharmaceutical compositions comprising an HMG-conreductase inhibitor compound | SANDOZ LTD (CH) | 1999-01-27 | — | — | CN | claimed |
| WO-1997049681-A1 | POLYMORPHIC COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1997-12-31 | — | — | WO | claimed |
| WO-1997026874-A1 | USE OF FLUVASTATIN DERIVATIVES IN SKIN DISEASE AND TOPICAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1997-07-31 | — | — | WO | claimed |
| US-5356896-A | Alkaline stabiling medium | SANDOZ LTD. (CH) | 1994-10-18 | — | — | US | claimed |
| CN-1091634-A | The stable pharmaceutical composition that contains a kind of β-Qiang Ji-β-Jia Jiwuersuandanxian coenzyme reductase inhibitor | SANDOZ LTD (CH) | 1994-09-07 | — | — | CN | claimed |
| EP-0547000-A1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | SANDOZ LTD. (CH) | 1993-06-16 | — | — | EP | claimed |